PharmaVentures Welcomes Samara Ferguson as Vice President

PharmaVentures Announces New Leadership in Pricing and Market Access
PharmaVentures is excited to share the news of Samara Ferguson's appointment as Vice President, taking charge of the vital Pricing and Market Access division. This strategic role will enhance their support for clients engaged in sell-side, buy-side, and licensing due diligence, as well as deal-making initiatives.
Samara Ferguson's Wealth of Experience
Samara boasts over 20 years of diverse experience within the pharmaceutical industry. She has developed a wealth of knowledge and expertise concerning market access, health economics, and outcomes research during her tenure at well-known companies like GSK, Amgen, and UCB. Her work includes supporting product portfolios at various stages, from clinical development all the way through to post-launch evaluation.
Expertise in Market Access Strategies
A key aspect of Samara's professional background includes her consultancy experience. This role has equipped her with deep insights into various therapy areas, where she has thoroughly tested market access and pricing potential. She excels in crafting market access strategies, evidence generation plans, and tailored real-world studies to support clients in making informed decisions.
Handling In-Licensing Opportunities
Throughout her career, Samara has proven instrumental in conducting rapid assessments of in-licensing opportunities. By identifying crucial areas of risk and potential, she aids organizations in making well-informed investment decisions.
Leadership Acknowledgement
Dr. Fintan Walton, Founder and CEO of PharmaVentures, expressed enthusiasm about Samara joining the team, stating, "We are delighted to welcome Samara to the PharmaVentures team. Her extensive experience working with major pharmaceutical companies, as well as her advisory roles for various small to mid-sized pharma operations, will greatly benefit our clients. High-quality pricing and market access support is essential in due diligence and securing optimal deal terms."
Educational Credentials
Samara holds a Master of Science in Health Economics and Health Policy from the University of Birmingham, which further strengthens her qualifications in this critical field.
Contact Information
For further inquiries, interested parties are encouraged to reach out to Rachel Hampstead for more information.
Frequently Asked Questions
What is the role of Samara Ferguson at PharmaVentures?
Samara Ferguson has been appointed as Vice President to lead the Pricing and Market Access team.
What experience does Samara Ferguson bring?
With over 20 years in the pharmaceutical industry, she specializes in market access, health economics, and outcomes research.
Who is the CEO of PharmaVentures?
Dr. Fintan Walton is the Founder and CEO of PharmaVentures.
What educational background does Samara Ferguson have?
She holds an MSc in Health Economics and Health Policy from the University of Birmingham.
How will Samara contribute to PharmaVentures?
Her extensive experience will enhance pricing and market access support, benefiting clients in due diligence and negotiations.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.